ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
GSK, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Viruses. 2024 Mar 6;16(3):405. doi: 10.3390/v16030405.
In GEMINI-1/-2, dolutegravir + lamivudine was non-inferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in achieving viral suppression (viral load [VL] < 50 copies/mL) in treatment-naive adults. Abbott's RealTime HIV-1 assay provides quantitative VL (40-10,000,000 copies/mL) and qualitative target detected or target not detected (TND) for VL < 40 copies/mL. This post hoc analysis assessed very-low-level viremia and "blips" through Week 144. Proportions with VL < 40 copies/mL and TND are presented overall and by baseline VL and CD4+ cell count. "Blips" (single VL ≥ 50 to <200 copies/mL with adjacent values < 50 copies/mL) were assessed from Day 1 after VL suppression and from Weeks 48 through to 144. Proportions with TND increased through Week 48 and were similar between groups at all visits (Week 144: dolutegravir + lamivudine, 451/716 [63%]; dolutegravir + TDF/FTC, 465/717 [65%]). By observed analysis, TND rates were similar between groups across baseline subgroups. Through Week 144, proportions with ≥1 "blip" were generally comparable for dolutegravir + lamivudine vs. dolutegravir + TDF/FTC from Day 1 (15% vs. 20%) and from Week 48 (7% vs. 11%). Through 144 weeks, the proportions with TND or "blips" were similar between dolutegravir + lamivudine and the three-drug comparator, reinforcing the efficacy and durability of dolutegravir + lamivudine.
在 GEMINI-1/-2 研究中，初治成人患者接受多替拉韦加拉米夫定（DTG+3TC）治疗与多替拉韦替诺福韦艾拉酚胺富马酸（TDF/FTC）相比，病毒学抑制率（病毒载量[VL]＜50 拷贝/ml）非劣效，雅培公司的 RealTime HIV-1 检测法可定量检测 VL（40-10,000,000 拷贝/ml）和定性检测 VL＜40 拷贝/ml 的结果（检测到或未检测到目标[TD]）。本事后分析评估了第 144 周时极低水平病毒血症和“VL 波动”。报告了总体和按基线 VL 和 CD4+细胞计数分层的 VL＜40 拷贝/ml 和 TND 的比例。从 VL 抑制后第 1 天和第 48 周到第 144 周评估“VL 波动”（单个 VL≥50 至＜200 拷贝/ml，相邻值＜50 拷贝/ml）。第 48 周至第 144 周时 TND 比例逐渐增加，各随访时间点两组间相似（第 144 周：DTG+3TC，451/716[63%]；DTG+TDF/FTC，465/717[65%]）。观察性分析显示，各组在所有基线亚组中 TND 发生率相似。至第 144 周，从第 1 天（15% vs. 20%）和第 48 周（7% vs. 11%）开始，DTG+3TC 组与 DTG+TDF/FTC 组“VL 波动”的比例大致相当。在第 144 周时，DTG+3TC 组与三药对照相比，TND 或“VL 波动”的比例相似，这进一步强化了 DTG+3TC 的疗效和持久性。
